Incanthera Chairman Tim McCarthy presented at the Proactive One2One Investor Forum on the company’s transition from oncology research to dermatology and its launch of the luxury skincare brand Skin + Cell.
McCarthy explained that Incanthera, originally spun out from the University of Bradford’s Institute of Cancer Therapeutics, has evolved from a loss-making biotech into a revenue-generating business through a direct-to-consumer (DTC) model. The company’s new range, Skin + Cell, features formulations built around bioactive vitamin B3 (Nicotinamide), designed to penetrate the skin effectively and support cell repair.
He said the “magic” lies not in the vitamin itself but in the patented formulation that allows the active ingredient to reach the dermal layer. The launch, which began in August, is supported by a global network of brand ambassadors and influencers reaching around 100 million consumers.
McCarthy highlighted that this strategy delivers immediate revenue, improved margins, and positive cash flow — a turning point for the company. He added that early consumer feedback has been “fantastic,” with many noticing visible skin improvements within weeks of use.
He concluded by noting that Incanthera plans to extend the range with products such as SPF formulations and is exploring additional routes to market.
#Incanthera #TimMcCarthy #SkinPlusCell #SkincareInnovation #Dermatology #Biotech #AquisExchange #VitaminB3 #Nicotinamide #DirectToConsumer #BeautyTech #SkinHealth #ProactiveInvestors
